Stevanato (STVN) makes the glass vials and pre-filled syringes that GLP-1 drugs ship in. The stock has sold off on fears that oral GLP-1s replace injectables, but Aurelian Research's Leo Trudel argues that's a misread: biologics demand keeps growing, the mix is shifting toward higher-margin "high-value solutions," and switching costs in regulated drug delivery are real. We dig into the bull case, the oral-vs-injectable debate, capacity and oversupply risk, capital allocation, regulatory lock-in, and what would change Leo's view.
[00:00:00] Podcast intro and guest welcome
[00:03:08] Stevanato's business model: vials, syringes, high-value solutions[
00:03:51] COVID boom and the destocking cycle
[00:06:39] Why the stock sold off and what it implies
[00:07:34] Market expectations vs. reality
[00:11:55] Margin expansion from mix shift
[00:14:40] Oral vs. injectable GLP-1s: the real debate
[00:17:30] Why oral and injectable aren't interchangeable
[00:19:44] Capacity additions and oversupply risk
[00:21:00] Biologics demand beyond GLP-1
[00:23:04] Management trust and capital allocation
[00:26:52] Regulatory lock-in: the real moat
[00:29:42] What could break the bull case
[00:30:53] Future capex and where it goes
[00:32:41] Industry structure and M&A outlook
[00:34:37] AI tools in investment research
[00:38:09] Closing thoughts and Leo's stance
Links:
Yet Another Value Blog - https://www.yetanothervalueblog.com
See our legal disclaimer here: https://www.yetanothervalueblog.com/p...
Production and editing by The Podcast Consultant - https://thepodcastconsultant.com/
